AVBP Reports $312.8M Cash, $312.8M Investments, Firmonertinib Phase 3 Data Mid‑2026, ADC ARR‑217 Phase 1, NMPA Approval China
ArriVent BioPharma, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $30.68
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS